531681 — Amerise Biosciences Income Statement
0.000.00%
Last trade - 00:00- IN₹56.82m
- IN₹56.66m
- IN₹0.36m
- 30
- 19
- 53
- 23
Annual income statement for Amerise Biosciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 90.1 | 0 | 0.359 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0.933 | 0 | 0.359 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.5 | 1.68 | 90.3 | 1.27 | 1.82 |
| Operating Profit | -1.5 | -1.68 | -0.203 | -1.27 | -1.46 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.49 | -3.37 | 5.49 | -1.19 | -1.46 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.49 | -3.37 | 5.49 | -1.19 | -1.46 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.49 | -3.37 | 5.49 | -1.19 | -1.46 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.49 | -3.37 | 5.49 | -1.19 | -1.46 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.023 | -0.051 | 0.083 | -0.018 | -0.022 |